LYEL Lyell Immunopharma, Inc.
NEUTRAL
Impact: 3/10
DEFA14A
Proxy solicitation materials
Latest settled — T+20d ⚠ clustered
LYEL ▼ -27.63% at T+20d
NEUTRAL call ✗ call lost -27.63% · α vs SPY -32.59% · entry $22.62 → $16.37
Currently $13.50 · -40.32% from $22.62 entry
T+1d
-5.00%
call -5.00% · α -4.51%
$21.49
settled 7w ago
T+5d
-8.40%
call -8.40% · α -8.80%
$20.72
settled 6w ago
T+20d
-27.63%
call -27.63% · α -32.59%
$16.37
settled 22d ago
T+60d
—
call — · α —
—
in 5w
Price Chart
Loading chart...
Executive Summary
Lyell Immunopharma filed a definitive proxy statement for its 2026 annual meeting, which includes routine director elections and executive compensation matters. The filing is standard for public companies and does not contain any material financial or strategic developments.
Actionable Insight
This is a routine annual filing with no material developments. Monitor the company's next earnings report for any significant updates.
Key Facts
- Filing is a standard DEFA14A proxy statement for the 2026 annual meeting
- Covers routine matters including director elections and executive compensation
- No material financial or strategic developments disclosed
- Standard annual filing for public companies
Financial Impact
No material financial impact from this filing
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-016688 |
| Document: 0001140361-26-016688-index-headers.html | 0001140361-26-016688 |
| Document: 0001140361-26-016688-index.html | 0001140361-26-016688 |
| Document: 0001140361-26-016688.txt | 0001140361-26-016688 |
10 reports for LYEL
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Press Release
| $13.32 awaiting T+20 | awaiting T+20 | — | $13.50 (+1.39%) |
|
Jun 8, 2026
5d ago
|
Press Release
| $11.94 awaiting T+20 | awaiting T+20 | — | $13.50 (+13.11%) |
|
Jun 4, 2026
8d ago
|
Press Release
| $13.02 awaiting T+20 | awaiting T+20 | — | $13.50 (+3.73%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $13.50 (−40.32%) |
|
Apr 15, 2026
8w ago
|
EFFECT
| $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $13.50 (−43.37%) |
|
Apr 3, 2026
10w ago
|
S-3
| $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $13.50 (−37.76%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $13.50 (−36.47%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $25.50 $21.78 | ▼ −14.59% | ▼ −11.78% | $13.50 (−47.06%) |
|
Mar 6, 2026
14w ago
|
Insider Cluster
| $22.46 $21.69 | ▼ −3.43% | ▼ −1.38% | $13.50 (−39.89%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $24.10 $19.29 | ▼ −19.96% | ▼ −12.02% | $13.50 (−43.98%) |
Showing 10 of 10
US Market Status
Market Closed — Opens Mon (48h 46m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access